General
Preferred name
BROTIZOLAM
Synonyms
Mederantil ()
WE-941-BS ()
WE 941 ()
WE-941 ()
Lendorm ()
Lendormin ()
Nimbisan ()
Sintonal ()
P&D ID
PD009405
CAS
57801-81-7
Tags
available
drug
First approval
1983
Drug Status
investigational
approved
withdrawn
Max Phase
Phase 3
Drug indication
Sedative-Hypnotic
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION Brotizolam is indicated for 2-4 weeks in the treatment of severe or debilitating insomnia.
Compound Sets
10
Cayman Chemical Bioactives
27779
ChEMBL Drugs
CHEMBL32479
DrugBank
DB09017
DrugCentral
409
DrugCentral Approved Drugs
409
DrugMatrix
Ki Database
Brotizolam
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL32479
NPC Screening Collection
Withdrawn 2.0
DB09017
External IDs
26
Properties
(calculated by RDKit )
Molecular Weight
391.95
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
1
Ring Count
4
Aromatic Ring Count
3
cLogP
4.4
TPSA
43.07
Fraction CSP3
0.13
Chiral centers
0.0
Largest ring
7.0
QED
0.61
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
ATC
N05CD09
Toxicity type
NULL
Source data